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Increased colistin resistance upon
acquisition of the plasmid-mediated mcr-1
gene in Escherichia coli isolates with
chromosomally encoded reduced
susceptibility to polymyxins
Sir,
Colistin is a last-resort antibiotic for treating infections due to
multidrug-resistant enterobacterial isolates. The emergence of chro-
mosomal mutations in genes involved in the modiﬁcation of
lipopolysaccharide, e.g. in pmrAB, is responsible for colistin resis-
tance [1,2]. However, the major source of concern is related to the
recent discovery of plasmid-mediated colistin resistance genes (mcr-1
to -3) owing to the risk of spread of colistin resistance [2,3]. In Es-
cherichia coli, chromosomally encoded PmrAB mutations and
plasmid-mediated colistin resistance are responsible for low levels
of colistin resistance [colistin minimum inhibitory concentrations
(MIC) < 16 mg/L] [2,4,5].
The objective of this study was to determine the level of colis-
tin resistance resulting from the combination of chromosomal
mutations and plasmid-mediated mcr-1 gene in E. coli.
Four E. coli isolates were used in this study, with isolates FRO
and MAL being recovered from human urine samples and isolate
41331 from an animal sample. The colistin-susceptible E. coli ref-
erence strain K12 was used for mating-out assays. MICs of colistin
were determined by broth microdilution method (BMD) as recom-
mended by the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) guidelines (http://www.eucast.org). Brieﬂy, BMD
manual panels were prepared extemporaneously in non-treated
96-well polystyrene microplates (Sarstedt, Nümbrecht, Germany).
Dilutions of colistin sulfate (Sigma-Aldrich, St Louis, MO) ranging
from 0.12–128 mg/L were made in cation-adjusted Mueller–
Hinton broth. The results were interpreted based on EUCAST
recommendations, with susceptibility and resistance breakpoints
being at ≤2 mg/L and >2 mg/L, respectively.
Isolate FRO showed decreased susceptibility to colistin, with an
MIC of 2 mg/L, and sequencing of the pmrAB genes identiﬁed an
amino acid substitution (L110*) in the PmrB protein known to be
responsible for an increased colistin MIC [4]. Isolate MAL showed
low-level colistin resistance (MIC = 8 mg/L) and sequencing iden-
tiﬁed an amino acid substitution (T114P) in the HAMP domain of
the PmrB protein (Table 1). Neither of the isolates presented mu-
tations in phoP, phoQ or mgrB genes.
Plasmid p41331 recovered from E. coli isolate 41331 (colistin
MIC = 8 mg/L) carried both the mcr-1 gene and the blaCTX-M-1 gene
encoding resistance to ticarcillin and broad-spectrum cephalosporins.
To determine the level of colistin resistance resulting from
acquisition of the plasmid-mediated mcr-1 gene in E. coli isolates
MAL and FRO, plasmid p41331 was ﬁrst transferred into E. coli
K12 by mating-out assay and was then transferred into the colistin-
resistant E. coli FRO andMAL isolates, respectively. To avoid selection
with colistin that could be responsible for acquisition of additional
mutations, the E. coli transconjugants carrying plasmid p41331
were selected using Luria–Bertani agar plates supplemented with
ticarcillin (100mg/L). Presence of themcr-1 gene in transconjugants
was conﬁrmed by PCR using speciﬁc primers as described previously
[6].
Determination of the MICs of the transconjugants revealed
that the E. coli K12 transconjugant (p41331-K12) presented a low
level of resistance (MIC = 4 mg/L), whereas E. coli FRO and MAL
transconjugants (harbouring plasmid p41331 in addition to
mutations in PmrB) exhibited higher MICs (8 mg/L and 32 mg/L,
respectively) (Table 1). Acquisition of the plasmid-mediated mcr-1
gene in isolates FRO and MAL was responsible for a four-fold in-
crease in the MICs of colistin compared with the parental strains
(2 mg/L to 8 mg/L for FRO and 8 mg/L to 32 mg/L for MAL).
This study indicates that an increase in resistance level to co-
listin may be achieved upon acquisition of the mcr-1 gene in
strains harbouring chromosomally encoded mutations. The two-
step process leading to a higher level of resistance to colistin
mirrors what is known for quinolone resistance, with a plasmid
determinant conferring low-level resistance that may facilitate
further selection of chromosomally encoding mechanisms even-
tually leading to high-level resistance [7]. These results further
highlight that acquisition of the mcr-1 gene may have a very sig-
niﬁcant clinical impact, contributing to a higher level of colistin
resistance.
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Table 1
Molecular features and colistin minimum inhibitory concentrations (MICs) of the
Escherichia coli parental strains and transconjugants.
Isolate a Molecular features Colistin
MIC
(μg/mL)
Other
antimicrobial
resistance
PmrA PmrB MCR-1 CTX-M
41331 WT WT + + 8 NAL, CIP
K12 WT WT – – 0.25 RIF, NAL
p41331-K12 WT WT + + 4 RIF, NAL
FRO WT L110 – – 2 None
P41331-FRO WT L110 + + 8 None
MAL WT T114P – – 8 SXT, NAL, CIP
p41331-MAL WT T114P + + 32 SXT, NAL, CIP
WT, wild type; NAL, nalidixic acid; CIP, ciproﬂoxacin; RIF, rifampin; SXT,
trimethoprim/sulfamethoxazole.
a 41331 was the donor strain for mating assay; K12, FRO and MAL were the
recipients.
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